Based on the metrics, I would recommend a HOLD on SUNPHARMA. The 12M return of 13.58% and Sharpe Ratio of 1.47 indicate a relatively strong performance, while the recent 6M and 3M returns are lackluster, suggesting a neutral stance until further clarity emerges.